CD274 and neoplasm: In an hPD-L1 knock-in MC38 tumor-bearing humanized PD-1 mouse model, mice received 5 mg/kg of anti-hPD-1 antibody (intraperitoneal (IP)—twice a week) as the control or 100 and 300 mg/kg of oral SPE.